Eliem Therapeutics EBIT 2021-2024 | CLYM
Eliem Therapeutics ebit from 2021 to 2024. Ebit can be defined as earnings before interest and taxes.
Eliem Therapeutics Annual EBIT (Millions of US $) |
2023 |
$-40 |
2022 |
$-45 |
2021 |
$-36 |
2020 |
$-21 |
Eliem Therapeutics Quarterly EBIT (Millions of US $) |
2024-06-30 |
$-56 |
2024-03-31 |
$-3 |
2023-12-31 |
$-5 |
2023-09-30 |
$-5 |
2023-06-30 |
$-7 |
2023-03-31 |
$-23 |
2022-12-31 |
$-10 |
2022-09-30 |
$-9 |
2022-06-30 |
$-14 |
2022-03-31 |
$-13 |
2021-12-31 |
$-11 |
2021-09-30 |
$-9 |
2021-06-30 |
$-9 |
2021-03-31 |
$-7 |
2020-12-31 |
|
2020-09-30 |
$-2 |
2020-06-30 |
$-2 |
Sector |
Industry |
Market Cap |
Revenue |
Medical |
MED-DRUGS |
$0.342B |
$0.000B |
Eliem Therapeutics Inc. is a clinical-stage biotechnology company. It focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Eliem Therapeutics Inc. is based in SEATTLE, United Kingdom.
|